CoupledCAR®, our proprietary immunotherapy platform for solid tumor research
CoupledCAR® is ICT’s proprietary immunotherapy platform designed to support research and development of cellular immunotherapies for solid tumors. The platform enables integrated immunotherapy design strategies to support advanced translational research in oncology.
GCC19CART, the leading product being developed to treat patients with R/R mCRC
Our lead program, GCC19CART, is developed under ICT’s CoupledCAR® platform and has demonstrated robust clinical activity in treating relapsed/refractory metastatic colorectal cancer (mCRC), with promising data from clinical trials in the United States. GCC19CART has the potential to become the First-in-Class CAR-T product globally approved for the treatment of colorectal cancer.
Phase 1 study of GCC19CART is enrolling patients with R/R mCRC in the U.S., at dose level 1(1 x 10^6 CAR-T/kg), among six patients, the objective response rate (ORR) was 33%；At dose level 2(2x 10^6 CAR-T/kg), among six patients, the ORR was 67%, and the mOS has not yet been reached.
The broad pipeline of CAR-T candidates targeting other solid tumor
We’re also expanding our CAR-T candidate portfolio to treat more types of solid tumors, such as prostate cancer（mCRPC）.
INSTACAR™, our integrated platform supporting CAR-T innovation
INSTACAR™ is ICT’s proprietary platform that enables key service capabilities essential for advancing personalized cellular therapies, including cryopreservation, immunotherapy research and development, medical diagnostics, and scientific research.
ARMOREDCAR™, our engineered enhancement platform for next-generation CAR-T therapies
ARMOREDCAR™ is ICT’s proprietary engineering framework designed to strengthen cellular therapies through targeted functional enhancements. The platform supports research and development in immunotherapy by enabling controlled cytokine modulation, improved tumor microenvironment resilience, and optimized CAR-T performance for advanced scientific and translational applications.
Better CAR-T Therapy for Solid Tumors
Discover our broad pipeline of CAR-T candidates targeting other solid tumors
